外源性葡萄糖依赖性促胰岛素多肽在长效胰高血糖素样肽1受体激动剂治疗基础上对2型糖尿病男性患者能量摄入、食欲或能量消耗无急性影响
随机双盲研究纳入22例接受二甲双胍和长效GLP-1受体激动剂治疗的2型糖尿病男性,比较GIP与生理盐水输注5小时的效果。GIP与安慰剂输注期间能量摄入、食欲和能量消耗相似,但GIP输注时血浆胰高血糖素和葡萄糖曲线下面积高于安慰剂。
要点
- GIP与安慰剂输注期间能量摄入相似(648±74 kcal vs 594±55 kcal,P=0.480)。
- 食欲指标和能量消耗在GIP与安慰剂输注期间相似。
- GIP输注时血浆胰高血糖素和葡萄糖曲线下面积显著高于安慰剂(P=0.026和P=0.017)。
核心结论
- 在2型糖尿病患者中,在二甲双胍和长效GLP-1受体激动剂治疗基础上输注GIP未影响能量摄入、食欲或能量消耗,但较安慰剂升高血浆葡萄糖。
- 这些结果表明联合GIP和GLP-1无急性有益效应。
研究设计与样本
- 随机双盲设计,22例接受二甲双胍和长效GLP-1受体激动剂治疗的2型糖尿病男性(平均±SEM HbA1c 6.8±0.1% [51±1.5 mmol/mol])。
- 受试者接受两次5小时连续输注(洗脱期≥3天):一次输注GIP(6 pmol/kg/min),另一次输注生理盐水(安慰剂)。
- 输注60分钟后进行液体混合餐试验,输注270分钟后提供随意餐以评估能量摄入(主要终点)。
主要发现
- GIP与安慰剂输注期间能量摄入相似(648±74 kcal vs 594±55 kcal,P=0.480)。
- 食欲指标和能量消耗在GIP与安慰剂输注期间相似。
- GIP输注时血浆胰高血糖素和葡萄糖曲线下面积高于安慰剂输注(P=0.026和P=0.017)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dual incretin receptor agonists in clinical development have shown reductions in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear. Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2 diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist. RESEARCH DESIGN AND METHODS: In a randomized, double-blind design, men with type 2 diabetes (n = 22, mean ± SEM HbA1c 6.8 ± 0.1% [51 ± 1.5 mmol/mol]) treated with metformin and long-acting GLP-1R agonists were subjected to two 5-h continuous infusions (separated by a washout period of ≥3 days): one with GIP (6 pmol/kg/min) and another with saline (placebo). After 60 min of infusion, a liquid mixed-meal test was performed, and after 270 min of infusion, an ad libitum meal was served for evaluation of energy intake (primary end point). RESULTS: Energy intake was similar during GIP and placebo infusion (648 ± 74 kcal vs. 594 ± 55 kcal, respectively; P = 0.480), as were appetite measures and energy expenditure. Plasma glucagon and glucose were higher during GIP infusion compared with placebo infusion (P = 0.026 and P = 0.017) as assessed by area under the curve. CONCLUSIONS: In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo. These results indicate no acute beneficial effects of combining GIP and GLP-1.
引用
- Bergmann NC, Gasbjerg LS, Heimbürger SM, et al. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care. 2020. PMID: 31949084. doi:10.2337/dc19-0578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。